Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zanzalintinib - Exelixis

Next Previous
X
Search
Drug Profile

Zanzalintinib - Exelixis

Alternative Names: XL-092

Latest Information Update: 29 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis
  • Class Amides; Antineoplastics; Cyclopropanes; Fluorobenzenes; Phenyl ethers; Quinolines; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto-oncogene protein c-mer inhibitors; Proto-oncogene protein c-met inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer; Renal cell carcinoma
  • Phase II/III Squamous cell cancer
  • Phase I Solid tumours

Most Recent Events

  • 26 Aug 2024 Northwestern University plans phase-II trial for Leiomyosarcoma(Metastatic disease, Unresectable/Inoperable, Late-stage disease, Monotherapy, Second-line therapy or greater) in USA (PO) in September 2024 , (NCT06571734)
  • 06 Aug 2024 Exelixis completes enrolment in the phase III STELLAR-303 trial for Colorectal cancer in US, Australia, Belgium, France, Germany, Hong Kong, Hungary, South Korea, New Zealand, Poland, Singapore, Spain, Taiwan, Thailand, Portugal and United Kingdom (NCT05425940)
  • 06 Aug 2024 Exelixis plans a phase III pivotal STELLAR-311 trial for pancreatic neuroendocrine tumours (pNET) and extra-pancreatic NET (epNET) in the first half of 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top